SEI Investments
PTGX icon

SEI Investments’s Protagonist Therapeutics PTGX Stock Holding History

SEI Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
92,749
+9,552
+11% +$998K 0.01% 1077
2026
Q1 		$8.77M Buy
83,197
+45,851
+123% +$4.06M 0.01% 1208
2025
Q4 		$3.26M Sell
37,346
-6,665
-15% -$546K ﹤0.01% 1602
2025
Q3 		$2.92M Sell
44,011
-921
-2% -$52.3K ﹤0.01% 1539
2025
Q2 		$2.48M Buy
44,932
+7,404
+20% +$355K ﹤0.01% 1563
2025
Q1 		$1.81M Buy
37,528
+12,960
+53% +$543K ﹤0.01% 1676
2024
Q4 		$948K Sell
24,568
-10,510
-30% -$458K ﹤0.01% 1967
2024
Q3 		$1.58M Sell
35,078
-6,685
-16% -$270K ﹤0.01% 1784
2024
Q2 		$1.45M Buy
41,763
+5
+0% +$146 ﹤0.01% 1770
2024
Q1 		$1.21M Buy
41,758
+4,529
+12% +$123K ﹤0.01% 1809
2023
Q4 		$854K Sell
37,229
-2,987
-7% -$52.3K ﹤0.01% 1927
2023
Q3 		$671K Sell
40,216
-31,800
-44% -$617K ﹤0.01% 2011
2023
Q2 		$1.99M Buy
72,016
+36,377
+102% +$910K ﹤0.01% 1634
2023
Q1 		$820K Sell
35,639
-306
-0.9% -$5.14K ﹤0.01% 1951
2022
Q4 		$392K Sell
35,945
-617
-2% -$5.21K ﹤0.01% 2117
2022
Q3 		$308K Sell
36,562
-84,443
-70% -$799K ﹤0.01% 2292
2022
Q2 		$957K Sell
121,005
-9,713
-7% -$117K ﹤0.01% 1851
2022
Q1 		$3.1M Sell
130,718
-1,595
-1% -$44.9K 0.01% 1353
2021
Q4 		$4.53M Buy
132,313
+86,138
+187% +$2.72M 0.01% 1187
2021
Q3 		$818K Sell
46,175
-60,359
-57% -$2.57M ﹤0.01% 1867
2021
Q2 		$4.78M Buy
106,534
+19,654
+23% +$649K 0.01% 1103
2021
Q1 		$2.25M Buy
+86,880
New +$2.2M 0.01% 1400

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

SEI Investments's PTGX Position: Q2 2026 in Review

SEI Investments increased its Protagonist Therapeutics (PTGX) stake by 11% in Q2 2026, buying an estimated $998K and bringing the position to 92,749 shares worth $11.4M. The position accounts for 0.01% of the portfolio, ranked #1077.

SEI Investments first reported a position in PTGX in Q1 2021 and has held it in 22 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • SEI Investments held 92,749 shares of Protagonist Therapeutics worth $11.4M as of Q2 2026.
  • SEI Investments bought 9,552 Protagonist Therapeutics shares in Q2 2026, an estimated $998K.
  • Protagonist Therapeutics made up 0.01% of SEI Investments's portfolio in Q2 2026, its #1077 holding.
  • SEI Investments first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.